Stock comparison
LeMaitre Vascular
Nektar Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
NKTR
Nektar Therapeutics
Market cap
$1.33B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | NKTR | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 37D | LMAT |
| Benjamin Graham | 89A | 56D | LMAT |
| Philip Fisher | 81C | 48D | LMAT |
| Peter Lynch | 67B | 3F | LMAT |
| Joel Greenblatt | 56D | 2F | LMAT |
| Charlie Munger | 68D | 39D | LMAT |
| Terry Smith | 69D | 43D | LMAT |
Side-by-side metrics
| Metric | LMAT | NKTR |
|---|---|---|
| Market cap | $2.23B | $1.33B |
| P/E (TTM) | 37.1x | - |
| EV/EBIT | 36.6x | - |
| ROIC (TTM) | 9.43% | -17.17% |
| Gross margin | 72.39% | 99.38% |
| Net margin | 24.35% | -2.84% |
| Revenue CAGR 5y | 12.75% | -14.2% |
| EPS CAGR 5y | 19.04% | - |
| Debt / Equity | 0.5x | 0.1x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Revenue CAGR 5y12.75%vs -14.2%+190%
- ROIC (TTM)9.43%vs -17.17%+155%
- Net margin24.35%vs -2.84%+109%
- Dividend yield0.84%vs 0.0%+100%
NKTR leads on
- P/E (TTM)-vs 37.1x+133%
- EV/EBIT-vs 36.6x+130%
- Debt / Equity0.1xvs 0.5x+69%
- Gross margin99.38%vs 72.39%+27%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.